Objectives {#sec1-0300060520926364}
==========

The occurrence of cancer is currently increasing because of an aging population, the prevalence of smoking, the lack of physical activity, and other lifestyle factors.^[@bibr1-0300060520926364]^ Cancer is a cellular abnormality initiated by uncontrolled growth caused by an accumulation of damage or mutations in genetically-mediated factors and environmental factors, resulting in cells evading the signal-mediated controls of cell growth and death.^[@bibr2-0300060520926364]^ Genetic factors have a greater effect on cancer initiation than environmental and lifestyle factors,^[@bibr3-0300060520926364]^ and a number of potential susceptibility genes and variations have been examined and identified to participate in cancer occurrence.

DNA damage repair involves known molecular pathways such as single-strand damage repair, double-strand break repair, and damage reversal.^[@bibr4-0300060520926364]^ Present evidence suggests that genes participating in the repair of DNA double-strand breaks might also be involved in modifying the risk of various cancers.^[@bibr5-0300060520926364]^ Among these, the x-ray cross-complementing group 4 gene (*XRCC4*), which is a specific member of the non-homologous end-joining system, encodes a protein that functions with DNA ligase IV and DNA-dependent protein kinase in repairing DNA double-strand breaks.^[@bibr6-0300060520926364]^ XRCC4 also plays a role in both non-homologous end joining and the completion of V(D)J recombination.

Full-length *XRCC4* is 276 kb long, contains 23 exons, and is located on chromosome 5q14.2. Mutations in *XRCC4* lead to a severely short stature, gonadal failure, microcephaly, and increased genomic instability.^[@bibr7-0300060520926364],[@bibr8-0300060520926364]^ Additionally, its mutations cause primordial dwarfism without immunodeficiency.^[@bibr9-0300060520926364]^ After *XRCC4* knockdown, triple-negative breast cancer cells showed significantly increased sensitivity to ionizing radiation,^[@bibr10-0300060520926364]^ while *XRCC4* expression was also shown to have a potential role in the radiotherapy effect in patients with esophageal squamous cell carcinoma.^[@bibr11-0300060520926364]^ Another study found that reducing *XRCC4* expression might be associated with improving the prognosis of liver cancer patients undergoing postoperative adjuvant transcatheter arterial chemoembolization.^[@bibr12-0300060520926364]^

*XRCC4* variations may increase the risk of cancer by influencing protein function. For example, rs1805377 (A\>G) in intron 7 appears to abolish an acceptor splice site in exon 8.^[@bibr13-0300060520926364]^ This polymorphic locus was reported to be involved in the occurrence of different cancers and the tumor diffusing capacity.^[@bibr14-0300060520926364][@bibr15-0300060520926364][@bibr16-0300060520926364][@bibr17-0300060520926364]--[@bibr18-0300060520926364]^ However, the findings of these studies are inconclusive because of small population sizes, genetic heterogeneity of samples, and other forms of possible confounding bias.

Meta-analysis is a useful method for identifying a common effect when considerable variation exists in study findings.^[@bibr19-0300060520926364]^ Another advantage is the increased sample size resulting from pooling relevant studies, which can, to some degree, decrease the occurrence of a false-positive or false-negative association generated by random error. Previous meta-analyses have investigated the association between *XRCC4* polymorphisms and the risk of cancer, but as the relevant reports accumulate, an exhaustive and updated meta-analysis should be conducted.^[@bibr20-0300060520926364][@bibr21-0300060520926364]--[@bibr22-0300060520926364]^ Thus, in the present study, we performed a meta-analysis including a larger number of studies than previously used to investigate the association between the *XRCC4* rs1805377 polymorphism and the risk of developing different cancers.

Methods {#sec2-0300060520926364}
=======

Identification of appropriate studies {#sec3-0300060520926364}
-------------------------------------

A search of English (PubMed, Web of Science, and Embase) and Chinese language (China National Knowledge Infrastructure) databases was carried out to identify appropriate studies for inclusion in the meta-analysis using the following keywords: *XRCC4*, rs1805377, and cancer. Reference lists of these studies were also reviewed to identify additional relevant studies.

Inclusion criteria were case--control studies involving cancer patients and reports of ATM allele and/or genotype frequencies. In the case of overlapping datasets, the most recent study was included. Exclusion criteria were the omission of healthy controls or duplication of previous data. With respect to studies lacking inclusion data, the authors were contacted by email to obtain missing information.

Data extraction {#sec4-0300060520926364}
---------------

### Data analysis {#sec5-0300060520926364}

Data extraction from the publications was performed independently by two investigators, Xin-yuan Zhang and Xiao-han Wei. Extracted data included the first author surname, publication year, geographic region, genotyping method, sample size, and number of genotypes reported for both patients and controls. Data pertaining to patient ethnicity, control source, and cancer type were also extracted with a view to determining the contributions of underlying characteristics to the study findings.

Trial sequential analysis (TSA) {#sec6-0300060520926364}
-------------------------------

TSA was performed to evaluate whether the present meta-analysis had a sufficient sample size to generate firm pooled results about the effect of interventions. Evaluation criteria and calculation parameters were based on previous studies.^[@bibr23-0300060520926364],[@bibr24-0300060520926364]^ TSA was conducted using TSA software (version 0.9.5.10; (<http://www.ctu.dk/tsa/>).

Statistical analysis {#sec7-0300060520926364}
--------------------

The chi-square goodness-of-fit test was used to calculate the Hardy--Weinberg equilibrium of control genotypes (significant at the 0.05 level), and odds ratios (ORs) and 95% confidence intervals (CIs) were employed to evaluate the strength of the association between rs1805377 and cancer. To calculate the pooled estimates of the ORs and 95% CIs among the studies, a random effects model was used to resolve inter-study heterogeneity.^[@bibr25-0300060520926364]^

For the measurement of pooled ORs, three genetic models (allele contrast, dominant, and recessive) were employed. As described in a previous study,^[@bibr26-0300060520926364]^ OR1 (AA vs. aa), OR2 (Aa vs. aa), and OR3 (AA vs. Aa) were compared, where A is the risk allele, from which the most appropriate genetic model was selected.^[@bibr27-0300060520926364],[@bibr28-0300060520926364]^

A Q statistic was used to evaluate the degree of inter-study heterogeneity, with the absence of heterogeneity being defined as *P* \> 0.05.^[@bibr29-0300060520926364],[@bibr30-0300060520926364]^ The I^2^ is the proportion of observed variance in effect size attributable to the true differences among studies. Additionally, the I^2^ value was used to measure the degree of heterogeneity, with \<25% representing low heterogeneity, 25% to 75% representing moderate heterogeneity, and \>75% representing high heterogeneity. Subgroup analysis was carried out for ethnicity (e.g., Asian, Caucasian), source of controls (e.g., hospital or population), and types of cancer (e.g., breast cancer, bladder cancer).

A sensitivity analysis was used to evaluate whether the pooled effect size was potentially influenced by a single study. Each study was omitted from the meta-analysis in turn, then significant alterations to the pooled effect size were evaluated.

Funnel plots were generated for each study to evaluate publication bias. The standard error of log(OR) was plotted against log(OR); when the plot was asymmetrical, bias was determined. Accordingly, for the determination of the degree of asymmetry, an Egger test was performed; *P* \< 0.05 indicated publication bias.^[@bibr31-0300060520926364]^

Stata version 10.0 (Stata Corp., College Station, TX, USA) was used to perform all statistical calculations.

In silico analysis {#sec8-0300060520926364}
------------------

To predict the potential association between rs1805377 and *XRCC4* expression, we conducted expression quantitative trait loci (eQTL) analysis using the GTEx portal website (<http://www.gtexportal.org/home/>).^[@bibr17-0300060520926364],[@bibr18-0300060520926364]^

Results {#sec9-0300060520926364}
=======

Online literature databases were used to identify relevant publications for inclusion in the meta-analysis. Twenty-four publications were included according to the established inclusion criteria.^[@bibr13-0300060520926364],[@bibr32-0300060520926364][@bibr33-0300060520926364][@bibr34-0300060520926364][@bibr35-0300060520926364][@bibr36-0300060520926364][@bibr37-0300060520926364][@bibr38-0300060520926364][@bibr39-0300060520926364][@bibr40-0300060520926364][@bibr41-0300060520926364][@bibr42-0300060520926364][@bibr43-0300060520926364][@bibr44-0300060520926364][@bibr45-0300060520926364][@bibr46-0300060520926364][@bibr47-0300060520926364][@bibr48-0300060520926364][@bibr49-0300060520926364][@bibr50-0300060520926364][@bibr51-0300060520926364][@bibr52-0300060520926364][@bibr53-0300060520926364]--[@bibr54-0300060520926364]^ A flow diagram of this process is shown in [Figure 1](#fig1-0300060520926364){ref-type="fig"}. Subjects involved in the studies are not overlapping. These 24 case--control studies collectively contained 9,633 cancer patients and 10,544 unaffected controls. Individuals with different genetic backgrounds and different types of cancer were included. The main characteristics of the included studies are listed in [Table 1](#table1-0300060520926364){ref-type="table"}. Genotype and allele frequencies of rs1805377 and the Hardy--Weinberg equilibrium (HWE) in the controls are summarized in [Table 2](#table2-0300060520926364){ref-type="table"}. Of the 24 studies, four publications deviated significantly from HWE.^[@bibr35-0300060520926364],[@bibr42-0300060520926364],[@bibr44-0300060520926364],[@bibr51-0300060520926364]^

![Flow diagram of literature screening.](10.1177_0300060520926364-fig1){#fig1-0300060520926364}

###### 

Baseline characteristics of qualified studies in this meta-analysis.

![](10.1177_0300060520926364-table1)

  Author          Year   Region              Ethnicity   Control source   Type of cancer                            Cases/controls
  --------------- ------ ------------------- ----------- ---------------- ----------------------------------------- ----------------
  Fu              2003   Taiwan              Asian       Hospital         Breast cancer                             254/379
  García-Closas   2006   USA                 Caucasian   Population       Breast cancer                             1898/1514
  Figueroa        2007   Spain               Caucasian   Hospital         Bladder cancer                            1150/1149
  Margulis        2008   USA                 Caucasian   Hospital         Renal cell carcinoma                      326/335
  Tseng           2008   Taiwan              Asian       Hospital         Oral cancer                               636/636
  Liu             2008   China               Asian       Hospital         Glioma                                    771/752
  Chiu            2008   Taiwan              Asian       Hospital         Oral cancer                               318/318
  Siraj           2008   Saudi Arabia        Asian       Population       Papillary thyroid cancer                  223/229
  Tseng           2009   Taiwan              Asian       Hospital         Non-small cell lung cancer                152/162
  Leudeke         2009   Germany             Caucasian   Hospital         Prostate cancer                           512/539
  Long            2010   China               Asian       Hospital         Gastric antrum adenocarcinoma             361/616
  Gomes           2010   Portugal            Caucasian   Hospital         Thyroid cancer                            109/217
  Shen            2010   USA and Australia   Caucasian   Population       Non-Hodgkin lymphoma                      1946/1808
  Rajaraman       2010   USA                 Caucasian   Hospital         Glioma, meningioma and acoustic neuroma   565/495
  Mandal          2011   India               Asian       Hospital         Prostate cancer                           192/224
  Mittal          2012   India               Asian       Hospital         Urothelial bladder cancer                 211/244
  Zhao            2013   China               Asian       Hospital         Glioma                                    384/384
  Liu             2014   China               Asian       Hospital         Hepatocellular carcinoma                  200/207
  Ding            2015   China               Asian       Hospital         Pancreatic cancer                         206/412
  Shen            2015   China               Asian       Hospital         Pancreatic cancer                         248/496
  Su              2015   China               Asian       Hospital         Glioma                                    162/324
  Jiao            2016   China               Asian       Hospital         Glioma                                    317/352
  Makkoch         2016   Thailand            Asian       Hospital         Hepatocellular carcinoma                  121/107
  Yang            2016   China               Asian       Hospital         Esophageal squamous cell carcinoma        189/189

###### 

Distribution of genotype and allele frequencies of the *XRCC4* rs1805377 polymorphism.

![](10.1177_0300060520926364-table2)

                  Genotype distribution         Allele frequency                                                     
  --------------- ----------------------- ----- ------------------ ----- ----- ----- ---------- ------ ------ ------ ------
  Fu              14                      102   135                24    159   196   0.2698     0.26   0.74   0.27   0.73
  García-Closas   1231                    285   20                 964   239   10    0.2494     0.89   0.11   0.89   0.11
  Figueroa        13                      232   841                12    168   852   0.2574     0.12   0.88   0.09   0.91
  Margulis        12                      82    229                13    58    262   0.0001     0.16   0.84   0.13   0.87
  Tseng           173                     127   18                 167   130   21    0.5210     0.74   0.26   0.73   0.27
  Liu             382                     312   53                 379   305   48    0.1985     0.72   0.28   0.73   0.27
  Chiu            173                     127   18                 167   130   21    0.5210     0.74   0.26   0.73   0.27
  Siraj           2                       13    33                 12    88    127   0.5168     0.18   0.82   0.25   0.75
  Tseng           83                      48    19                 83    59    9     0.7266     0.71   0.29   0.75   0.25
  Leudeke         8                       107   422                8     89    410   0.2200     0.11   0.89   0.10   0.90
  Long            96                      173   92                 340   205   71    \<0.0001   0.51   0.49   0.72   0.28
  Gomes           1                       15    93                 6     45    166   0.1793     0.08   0.92   0.13   0.87
  Shen            29                      253   795                33    229   831   0.0007     0.14   0.86   0.13   0.87
  Rajaraman       10                      103   413                7     115   347   0.4665     0.12   0.88   0.14   0.86
  Mandal          131                     55    6                  149   65    10    0.4000     0.83   0.17   0.81   0.19
  Mittal          140                     70    1                  156   79    9     0.7969     0.83   0.17   0.80   0.20
  Zhao            179                     143   62                 195   153   36    0.4537     0.65   0.35   0.71   0.29
  Liu             122                     60    18                 124   66    17    0.0618     0.76   0.24   0.76   0.24
  Ding            74                      95    37                 159   184   69    0.2079     0.59   0.41   0.61   0.39
  Shen            92                      112   44                 201   216   79    0.1043     0.60   0.40   0.62   0.38
  Su              62                      70    30                 137   134   53    0.0413     0.60   0.40   0.63   0.37
  Jiao            173                     121   22                 197   132   23    0.8884     0.74   0.26   0.75   0.25
  Makkoch         60                      66    12                 55    42    10    0.6322     0.67   0.33   0.71   0.29
  Yang            95                      80    14                 88    83    18    0.8052     0.71   0.29   0.69   0.31

Abbreviation: *P*~HWE~ represents the *P* value of the Hardy--Weinberg equilibrium test in the genotype distribution of controls.

Meta-analysis {#sec10-0300060520926364}
-------------

Pooled ORs (with 95% CIs) in dominant, recessive, homozygous codominant, heterozygous codominant, and allele contrast genetic models were employed to evaluate the association of the rs1805377 polymorphism with cancer risk ([Table 3](#table3-0300060520926364){ref-type="table"} and [Figure 2](#fig2-0300060520926364){ref-type="fig"}). The dominant model was selected to perform the pooled analysis according to the selection criteria of genetic models. The pooled results showed that there was no association between rs1805377 and the risk of cancer. The summary OR under a random effects model was 1.107 (95% CI = 0.955--1.284). Subsequent subgroup analysis also failed to detect any association of rs1805377 with cancer risk among East Asian and Caucasian patients ([Table 4](#table4-0300060520926364){ref-type="table"}). Moreover, no association between rs1805377 and cancer was observed by subgroup analysis with respect to the control source (hospital or population). However, subgroup analysis according to cancer type revealed an association between rs1805377 and gastric antrum adenocarcinoma, but not other cancer types ([Table 4](#table4-0300060520926364){ref-type="table"}).

###### 

Summarized ORs with 95% CIs for the association of the XRCC4 rs1805377 polymorphism with cancer.

![](10.1177_0300060520926364-table3)

  Polymorphism   Genetic model             n    Statistical model   OR      95% CI         *p* ~z~   I^2^(%)   *p* ~h~   *p* ~e~
  -------------- ------------------------- ---- ------------------- ------- -------------- --------- --------- --------- ---------
  Rs1805377                                                                                                              
                 Allele contrast           24   Random              1.062   0.944--1.194   0.316     56.7      \<0.001   0.919
                 Homozygous codominant     24   Random              1.198   0.949--1.513   0.129     63.5      \<0.001   0.037
                 Heterozygous codominant   24   Random              1.097   0.960--1.255   0.174     57.6      \<0.001   0.747
                 Dominant                  24   Random              1.107   0.955--1.284   0.176     68.4      \<0.001   0.976
                 Recessive                 24   Random              1.110   0.939--1.312   0.221     69.1      \<0.001   0.360

Note: n, the number of studies; OR, odds ratio; CI, confidence interval; *p*~z~, *P* value for association test; *p*~h~, *P* value for heterogeneity test; *p*~e~, *P* value for publication bias test.

![Forest plot of the association between the *XRCC4* rs1805377 polymorphism and cancer in the dominant genetic model (GG + GA vs. AA).](10.1177_0300060520926364-fig2){#fig2-0300060520926364}

###### 

Stratified analysis of the association of the *XRCC4* polymorphisms with cancer under the dominant model.

![](10.1177_0300060520926364-table4)

                             rs1805377                                         
  -------------------------- ----------- ------- -------------- ------- ------ ---------
  Overall                    24          1.107   0.955--1.284   0.176   68.4   \<0.001
  **Ethnicity**                                                                
  East Asians                16          1.125   0.935--1.354   0.212   78.0   \<0.001
  Caucasians                 8           0.986   0.839--1.159   0.865   0.0    0.969
  **Source of controls**                                                       
  Hospital                   21          1.115   0.942--1.320   0.204   71.4   \<0.001
  Population                 3           0.981   0.824--1.169   0.832   0.0    0.796
  **Type of cancer**                                                           
  Breast cancer              2           0.971   0.811--1.164   0.752   0.0    0.623
  Bladder cancer             2           0.913   0.645--1.292   0.606   0.0    0.864
  Oral cancer                2           0.927   0.744--1.156   0.500   0.0    1.000
  Glioma                     5           1.077   0.941--1.233   0.280   0.0    0.863
  Thyroid cancer             2           1.728   0.499--5.987   0.388   0.0    0.512
  Prostate cancer            2           0.944   0.646--1.380   0.766   0.0    0.803
  Pancreatic cancer          2           1.140   0.903--1.438   0.271   0.0    0.900
  Hepatocellular carcinoma   2           1.106   0.779--1.570   0.572   18.6   0.268

Note: n, the number of studies; OR, odds ratio; CI, confidence interval; *p*~z~, *P* value for association test; *p*~h~, *P* value for heterogeneity test. The subgroup with only one study is not shown.

Sensitivity analysis {#sec11-0300060520926364}
--------------------

Sensitivity analysis was used to evaluate the extent to which each individual study contributed to the pooled results. Each study was eliminated from the analysis in turn, then pooled ORs were determined. No significant changes were detected between any of the analyses or the overall results; thus, we can be confident that the results of the meta-analysis display stability and reliability.

Assessment of publication bias {#sec12-0300060520926364}
------------------------------

A funnel plot ([Figure 3](#fig3-0300060520926364){ref-type="fig"}) was generated to assess publication bias, from which no significant effects were detected ([Table 3](#table3-0300060520926364){ref-type="table"}).

![Funnel plot analysis depicting publication bias in the association between the *XRCC4* rs1805377 polymorphism and cancer risk.](10.1177_0300060520926364-fig3){#fig3-0300060520926364}

TSA {#sec13-0300060520926364}
---

In the overall analysis for dominant genetic model, the required sample size was 106,055 patients to reach the anticipated intervention effect ([Figure 4](#fig4-0300060520926364){ref-type="fig"}). Results showed that the Z-curve did not cross the trail monitoring boundary, indicating that the present sample size was not sufficient and that further trials are required.

![TSA for overall analysis under the dominant genetic model.](10.1177_0300060520926364-fig4){#fig4-0300060520926364}

In silico analysis {#sec14-0300060520926364}
------------------

eQTL analysis found that, compared with the A allele, the G allele of the rs1805377 locus leads to increased expression of *XRCC4* mRNA ([Figure 5](#fig5-0300060520926364){ref-type="fig"}).

![In silico analysis of *XRCC4* expression with the rs1805377 polymorphism.](10.1177_0300060520926364-fig5){#fig5-0300060520926364}

Discussion {#sec15-0300060520926364}
==========

The relationship between the *XRCC4* rs1805377 polymorphism and cancer occurrence was explored in the present study using a meta-analysis consisting of 23 case--control studies. Our results indicated no association of this polymorphism with cancer risk except for gastric antrum adenocarcinoma.

Previously, a putative association of rs1805377 with cancer occurrence was analyzed in three meta-analyses.^[@bibr20-0300060520926364][@bibr21-0300060520926364]--[@bibr22-0300060520926364]^ While our meta-analysis overlaps somewhat with prior analyses, we included new analyses that have been conducted since these studies were published. Twenty-four studies were included to comprehensively investigate the role of rs1805377 in the occurrence of cancer. These consisted of patients with various types of cancer (breast cancer, bladder cancer, renal cell carcinoma, oral cancer, glioma, thyroid cancer, non-small-cell lung cancer, prostate cancer, gastric antrum adenocarcinoma, non-Hodgkin lymphoma, pancreatic cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma). With a view to evaluating the potential origins of heterogeneity and measuring stability, we performed subgroup analyses by ethnicity, control source, and cancer type. Therefore, to some extent, the final results of our meta-analysis are more accurate and comprehensive than previous meta-analyses.

There was considerable heterogeneity in our meta-analysis, which might reflect differences in genetic backgrounds. In subgroup analysis by ethnicity, we observed no significant heterogeneity in the East Asian subgroup, but strong heterogeneity in the Caucasian subgroup. This latter subgroup consisted of eight studies, including patients from the USA, Spain, Saudi Arabia, Germany, Portugal, and Australia. The observed heterogeneity may reflect the varied lifestyles and wide distribution of Caucasians, which can give rise to different cancer risks.^[@bibr55-0300060520926364]^

Our ability to conclusively define stable effects by subgroup, however, is limited by the relatively small sample size included in the subgroup analyses, particularly regarding cancers such as renal cell carcinoma, non-small cell lung cancer, gastric antrum adenocarcinoma, non-Hodgkin lymphoma, hepatocellular carcinoma, and esophageal squamous cell carcinoma. Our meta-analysis found an association between rs1805377 and the risk of gastric antrum adenocarcinoma, but this result should be interpreted with caution as only one study involving gastric antrum adenocarcinoma patients was included. Thus, we cannot conclude whether rs1805377 is associated with risk of cancer in these subgroups because of the limited sample size.

XRCC4 is required for non-homologous end joining, which is one of the major pathways for repairing DNA double-strand breaks. In its abnormal state it can lead to severe combined immunodeficiency,^[@bibr9-0300060520926364]^ but one reported patient with mutations in *XRCC4* displayed microcephaly and progressive ataxia but a normal immune response, suggesting that a XRCC4 deficiency can cause a marked neurological phenotype but no overt immunodeficiency.^[@bibr56-0300060520926364]^ Moreover, the *XRCC4* c.482G\>A mutation, which affects the last nucleotide of exon 4, induces defective splicing of *XRCC4* pre-mRNA leading to premature protein truncation and likely loss of XRCC4 function.^[@bibr8-0300060520926364]^ Additionally, genome-wide expression analysis revealed age-related impairment of mitosis, telomere and chromosome maintenance, and the induction of genes associated with DNA repair and non-homologous end-joining, most notably *XRCC4* and ligase 4.^[@bibr57-0300060520926364]^ Considering the inconsistency of the current results, more efforts are needed to explore the role of *XRCC4* mutations in the occurrence of cancer.

Conclusion {#sec16-0300060520926364}
==========

The present study demonstrated no association between the XRCC4 rs1805377 polymorphism and cancer risk. Additional studies involving a wider range of ethnicities are now required to validate our subgroup analyses. Furthermore, environmental and epigenetic factors that contribute to cancer risk should also be studied.
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